Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA): JAMA Oncology

V. Silvestri, G. Leslie, D.R. Barnes, B.A. Agnarsson, K. Aittomäki, E. Alducci, I.L. Andrulis, R.B. Barkardottir, A. Barroso, D. Barrowdale, J. Benitez, B. Bonanni, A. Borg, S.S. Buys, T. Caldés, M.A. Caligo, C. Capalbo, I. Campbell, W.K. Chung, K.B.M. ClaesS.V. Colonna, L. Cortesi, F.J. Couch, M. De La Hoya, O. Diez, Y.C. Ding, S. Domchek, D.F. Easton, B. Ejlertsen, C. Engel, D.G. Evans, L. Feliubadalò, L. Foretova, F. Fostira, L. Géczi, A.-M. Gerdes, G. Glendon, A.K. Godwin, D.E. Goldgar, E. Hahnen, F.B.L. Hogervorst, J.L. Hopper, P.J. Hulick, C. Isaacs, A. Izquierdo, P.A. James, R. Janavicius, U.B. Jensen, E.M. John, V. Joseph, I. Konstantopoulou, A.W. Kurian, A. Kwong, E. Landucci, F. Lesueur, J.T. Loud, E. Machackova, P.L. Mai, K. Majidzadeh-A, S. Manoukian, M. Montagna, L. Moserle, A.M. Mulligan, K.L. Nathanson, H. Nevanlinna, J. Ngeow Yuen Ye, L. Nikitina-Zake, K. Offit, E. Olah, O.I. Olopade, A. Osorio, L. Papi, S.K. Park, I.S. Pedersen, P. Perez-Segura, A.H. Petersen, P. Pinto, B. Porfirio, M.A. Pujana, P. Radice, J. Rantala, M.U. Rashid, B. Rosenzweig, M. Rossing, M. Santamariña, R.K. Schmutzler, L. Senter, J. Simard, C.F. Singer, A.R. Solano, M.C. Southey, L. Steele, Z. Steinsnyder, D. Stoppa-Lyonnet, Y.Y. Tan, M.R. Teixeira, S.H. Teo, M.B. Terry, M. Thomassen, A.E. Toland, S. Torres-Esquius, N. Tung, C.J. Van Asperen, A. Vega, A. Viel, J. Vierstraete, B. Wappenschmidt, J.N. Weitzel, G. Wieme, S.-Y. Yoon, K.K. Zorn, L. Mcguffog, M.T. Parsons, U. Hamann, M.H. Greene, J.A. Kirk, S.L. Neuhausen, T.R. Rebbeck, M. Tischkowitz, G. Chenevix-Trench, A.C. Antoniou, E. Friedman, L. Ottini

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA): JAMA Oncology'. Together they form a unique fingerprint.

Medicine & Life Sciences